Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841621 | 0.74 | FGFR1 (0.42) | CLK4FGFR1MAP2K2MAPK9NTRK1 | |
| SCHEMBL399440 | 0.74 | CHEK1 (0.32) | CDK8ROCK1KDRDYRK1APRKACA | |
| SCHEMBL1154880 | 0.73 | CDK8 (0.41) | CLK4CDK8ROCK1KDRDYRK1A | |
| SCHEMBL14638753 | 0.73 | ADORA3 (0.44) | CLK4CDK8ROCK1KDRDYRK1A | |
| SCHEMBL9611703 | 0.73 | CDK8 (0.44) | CLK4CDK8ROCK1KDRDYRK1A | |
| SCHEMBL5487082 | 0.71 | SMPD3 (0.38) | CLK4FGFR1MAP2K2MAPK9NTRK1 | |
| SCHEMBL334306 | 0.71 | CDK8 (0.53) | CLK4CDK8ROCK1KDRDYRK1A | |
| SCHEMBL24579491 | 0.70 | CDK8 (0.36) | CLK4CDK8ROCK1KDRDYRK1A | |
| Hydrochloric Acid SCHEMBL5442637 | 0.70 | CDK8 (0.52) | CLK4CDK8ROCK1KDRDYRK1A | |
| SCHEMBL23979526 | 0.70 | CDK8 (0.39) | CLK4CDK8ROCK1KDRDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-118063491-A | Imide catalyst auxiliary agent, polyimide film and preparation method | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023049723-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20220274990-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2022-09-01 | — | — | US | disclosed |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| EP-3980422-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114269748-A | Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer | 米拉蒂医疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CLK4 429/4885FGFR1 102/4885MAP2K2 5/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CLK4 429/4885FGFR1 102/4885MAP2K2 5/4885 |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | ADORA2A, ADORA1, ADORA3 | CLK4 3725/4885FGFR1 1690/4885MAP2K2 2737/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | CLK4 3599/4885FGFR1 1996/4885MAP2K2 2530/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | CLK4 3599/4885FGFR1 1996/4885MAP2K2 2530/4885 |
| US-20220274990-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | CLK4 3599/4885FGFR1 1996/4885MAP2K2 2530/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | CLK4 429/4885FGFR1 102/4885MAP2K2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.